Navigation Links
Sunesis Pharmaceuticals Reports Fourth Quarter and Full-Year 2007 Financial Results
Date:3/11/2008

continues to pursue

development of SNS-595 in acute myeloid leukemia (AML). A Phase 1b

clinical trial of SNS-595 in combination with cytarabine in relapsed

or refractory AML patients is in progress. Sunesis plans to begin

enrollment in a Phase 2 clinical trial of SNS-595 on a weekly dose

schedule in previously untreated elderly AML patients in the first

half of 2008. Sunesis expects to report data later this year for

both AML clinical trials.

-- Results from a non-clinical study of SNS-032, a potent and selective

inhibitor of cyclin-dependent kinases (CDKs) 2, 7 and 9, were presented

at ASH. These data demonstrated that SNS-032 induces apoptosis in

chronic lymphocytic leukemia (CLL) cells. Furthermore, SNS-032's in

vitro activity compared favorably with flavopiridol in CLL cells

obtained from patients. SNS-032 currently is in a Phase 1 clinical

trial of patients with relapsed or refractory CLL or multiple myeloma.

To date, the drug has been well tolerated in this trial, and dose

escalation in both indications is expected to be completed this year.

-- Sunesis is continuing enrollment in its Phase 1 dose-escalating trial

of SNS-314, a potent and selective inhibitor of Aurora kinases A, B and

C, in advanced solid tumors. To date, SNS-314 has been well tolerated

and no dose-limiting toxicities have been observed. The company

expects to identify a maximum-tolerated dose in this Phase 1 clinical

trial this year.

-- In December, Sunesis and the Multiple Myeloma Research Consortium

(MMRC) announced a collaboration to evaluate the preclinical activity

of SNS-032 in multiple myeloma-relevant models and in primary disease

tissue, extending non-clinical studies performed by Sunesis.

-- In February 2008, Sunesis received
'/>"/>

SOURCE Sunesis Pharmaceuticals
Copyright©2008 PR Newswire.
All rights reserved

Page: 1 2 3 4 5 6 7 8 9 10

Related biology technology :

1. Sunesis Pharmaceuticals to Present Interim Phase 2 Data for SNS-595 at the 39th Annual Meeting on Womens Cancer
2. Sunesis Pharmaceuticals Announces Milestone Payment from Inflammation Collaboration
3. Sunesis Pharmaceuticals Appoints Lesley A. Stolz, Ph.D., Vice President, Corporate and Business Development
4. Sunesis Pharmaceuticals to Report Third Quarter 2007 Financial Results
5. Sunesis Pharmaceuticals to Present Data at the AACR-NCI-EORTC International Conference on Molecular Targets and Cancer Therapeutics
6. Sunesis Pharmaceuticals Announces Reorganization to Focus Resources and Build Value in Clinical-Stage Programs
7. Peregrine Pharmaceuticals Reports Financial Results for the Third Quarter of Fiscal Year 2008
8. Alseres Pharmaceuticals Presents Inosine and Dopamine Transporter (DAT) Blocker Preclinical Data at the American Society for Experimental NeuroTherapeutics (ASENT) Conference
9. Keryx Biopharmaceuticals Announces that SUN-MICRO Phase 3 Clinical Trial Fails to Meet Primary Efficacy Endpoint
10. Cadence Pharmaceuticals to Host Conference Call and Webcast to Discuss Fourth Quarter and Full Year 2007 Financial Results and Clinical Program Overview on March 12, 2008
11. Jazz Pharmaceuticals, Inc. Announces Webcast of March 13 Investor Meeting
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:9/16/2014)... , Sept. 16, 2014  The Council ... entrepreneurial support organization in the country, today released ... Report . It showed that ... North Carolina startups in the technology, ... more global investment from a variety of sources. Significant ...
(Date:9/16/2014)... Sept. 16, 2014 /PRNewswire-iReach/ -- Researchers found that ... identifies patients with bone fragility fracture when today,s ... people worldwide are at risk of fracture for ... bone strength test, the DEXA bone density scan. ... for Bone and Mineral Research Annual Conference (ASBMR) ...
(Date:9/16/2014)... RENU 28, the world's first and only skin gel ... in Australia and New Zealand in mid-August . , The ... tour will make stops in Brisbane on September 16, the ... on the 20th, and Melbourne on the 22nd. , Helping ... to educate people about the new product and business opportunity ...
(Date:9/15/2014)... JOSE, Calif. , Sept. 15, 2014 /PRNewswire/ ... Proposals (RFP) for flexible, printed product demonstrators (demos) ... a two-stage RFP process with pre-proposals due on ... January 2015.  Funds for proposals ultimately selected are ... and have a significant cost share by the ...
Breaking Biology Technology:CED's Mid-Year Update to its Innovators Report Shows NC Startups Attracting Investment From Across the Globe with Several High-Profile Investment Deals, IPOs and Acquisitions Signaling Strength of Entrepreneurial Sector 2CED's Mid-Year Update to its Innovators Report Shows NC Startups Attracting Investment From Across the Globe with Several High-Profile Investment Deals, IPOs and Acquisitions Signaling Strength of Entrepreneurial Sector 3CED's Mid-Year Update to its Innovators Report Shows NC Startups Attracting Investment From Across the Globe with Several High-Profile Investment Deals, IPOs and Acquisitions Signaling Strength of Entrepreneurial Sector 4ActiveLife's BMSi Test Provides Hope for 160 Million with Undetectable Risk of Bone Fracture 2ActiveLife's BMSi Test Provides Hope for 160 Million with Undetectable Risk of Bone Fracture 3Global Wellness Company Hosts ASEA Australia Tour September 16-22 2FlexTech Alliance Issues 2015 Request for Proposals in Flexible, Printed Electronics 2
... , NOVATO, Calif., Sept. 8 BioMarin Pharmaceutical Inc. ... Officer of BioMarin, will present a company update at the Morgan Stanley ... 1:35 p.m. ET. , , Interested parties ... investor section of the BioMarin website, www.BMRN.com . ...
... , SAN DIEGO, Sept. 8 eBioscience Corporation, a ... the acquisition of NatuTec GmbH, a leading distributor of high-quality biological ... , "For the past 10 years, NatuTec has ... R. Nelson, CEO of eBioscience. "The NatuTec acquisition provides eBioscience ...
... LAIYANG, China, Sept. 8 /PRNewswire-Asia-FirstCall/ -- ... a,U.S. pharmaceutical company with its principal operations in the ... for,fiscal year 2009. The Company expects to meet ... revenue and operating income of $40 to $43 million ...
Cached Biology Technology:BioMarin to Present at the Morgan Stanley Healthcare Conference 2eBioscience Corporation Acquires NatuTec GmbH 2Jiangbo Pharmaceuticals Reaffirms Guidance for Fiscal 2009 2
(Date:9/16/2014)... YORK (17 September, 2014)More than $100 trillion in ... of annual carbon dioxide (CO2)a 40 percent reduction ... 2050 if the world expands public transportation, walking ... report released by the University of California, Davis, ... (ITDP). , Further, an estimated 1.4 million ...
(Date:9/16/2014)... its own bacterial identity. That,s the conclusion of University ... studied the genetic fingerprints of bacteria on 57 species ... study demonstrates for the first time that host plants ... possess very different microbial communities on their leaves," said ... in the UO,s Institute of Ecology and Evolution who ...
(Date:9/16/2014)... the Keystone XL pipeline (KXL) would likely increase oil ... researchers surveyed by the non-profit organization Near Zero. The ... Climate Impact," and includes both supporters and opponents of ... oil sands could lead to significantly higher greenhouse gas ... markets respond. , "This report examines three main ...
Breaking Biology News(10 mins):Global shift away from cars saves US$100 trillion, eliminates 1,700 MT of CO2 pollution 2Global shift away from cars saves US$100 trillion, eliminates 1,700 MT of CO2 pollution 3Global shift away from cars saves US$100 trillion, eliminates 1,700 MT of CO2 pollution 4Global shift away from cars saves US$100 trillion, eliminates 1,700 MT of CO2 pollution 5Microbiome research shows each tree species has a unique bacterial identity 2Keystone XL would likely raise oil sands production and greenhouse gas emissions 2
... For the first time in nearly a century drinkers will ... heritage barley from the Victorian period. Old varieties ... the John Innes Centre revived Chevallier from the institute,s Genetic ... records indicate that the variety produced premium quality malt and ...
... analysis, carbon dioxide removal could be used under certain ... but it would not replace the bulk of actual ... allows to separate emissions control from the time and ... important for climate protection," says lead-author Elmar Kriegler. "You ...
... "Many of the great whales which once populated the oceans ... commercial hunting. The committee also worried about how tuna fishing ... And they considered reports about seal hunting and the decline ... October of that year, Congress passed the Marine Mammal Protection ...
Cached Biology News:Cheers to better beer and disease resistance 2CO2 removal can lower costs of climate protection 2CO2 removal can lower costs of climate protection 3Sea mammals find US safe harbor 2Sea mammals find US safe harbor 3Sea mammals find US safe harbor 4
Affinity Purified Rabbit Anti-mouse sRANKL Biotinylated Polyclonal Antibody...
Polyclonal antiserum raised against conjugated L-isoleucine. Available as antiserum. Amino Acid Antibodies...
... in heart tissues, and is produced ... conditions. Treatment of cells with ... TIMP-4 in some cell types, but ... require concentration of cell culture media ...
Mouse monoclonal [002-49] to C1s ( Abpromise for all tested applications). entrezGeneID: 716 SwissProtID: P09871...
Biology Products: